Background: Maintaining continuous pharmacological treatment of patients with dementia is often difficult. In the current study we surveyed the discontinuation of donepezil, a cholinesterase inhibitor, for the treatment of Alzheimer's disease in a Japanese geriatric outpatient clinic in a university hospital.
Methods: Using a retrospective chart review from 1 July 2003 to 30 June 2005, prescriptions of donepezil and the reasons for discontinuing the prescription in a university hospital were determined. The severity of dementia was evaluated by the clinical dementia rating (CDR).
Results: Out of 264 patients, 140 (53.1%) discontinued taking donepezil during the two-year observation period. The mean age of the continued group and the discontinued group did not differ significantly (79.5 +/- 6.7, 79.8 +/- 6.4, respectively). Kaplan-Meier analysis showed that the patients with more severe cognitive impairment (CDR score = 3) discontinued donepezil earlier and more frequently. The reasons for discontinuation were a change in the doctors treating the patients (n = 71), ineffectiveness (n = 16), gastrointestinal side-effects (n = 11), and others (n = 41). In patients with CDR = 1 or 2, changes of doctors were the most frequent reason for discontinuation. However, in patients with CDR = 3, ineffectiveness of the medication was the major reason for discontinuation.
Conclusion: Donepezil was frequently discontinued, and the rate of discontinuation was higher in patients with advanced dementia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1017/S1041610208007011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Donepezil and Memantine-Induced Second-Degree Atrioventricular Block: A Case Report.
Hosp Pharm
October 2024
Department of Psychiatry, JSS Medical College & Hospital, JSS Academy of Higher Education and Research, Mysore, Karnataka, India.
Article Synopsis
- Donepezil and memantine are second-generation medications used for managing mild to moderate Alzheimer's disease, acting on different neural pathways to help with cognitive decline.
- Donepezil inhibits acetylcholinesterase, while memantine blocks NMDA receptors, both targeting the central nervous system.
- A case study of an 81-year-old male with Alzheimer's and schizophrenia revealed he developed a second-degree atrioventricular block after taking these drugs, but his condition improved within 2 to 3 weeks after stopping the medications and receiving short-term treatment.
Background: Donepezil, an acetylcholinesterase inhibitor commonly used to treat Alzheimer's disease (AD), is generally well tolerated. There have been no previous reports on donepezil-induced obsessive-compulsive disorder (OCD).
Case Presentation: The patient, a retired man in his 70s diagnosed with AD, displayed OCD symptoms following donepezil initiation, exacerbating post-stroke-specifically, a cerebral infarction in the right posterior limb of the internal capsule.
Changes in dementia treatment patterns associated with changes in the National Policy in South Korea among patients with newly diagnosed Alzheimer's disease between 2011 and 2017: results from the multicenter, retrospective CAPTAIN study.
BMC Public Health
January 2024
National Health Insurance Service Ilsan Hospital, Goyang-si, Gyeonggi-do, South Korea.
Article Synopsis
- - The South Korean government has been implementing strategies since 2008 to combat dementia, including expanding long-term care insurance (LTCI) eligibility for people with dementia in 2014, which provided better access to care services.
- - A study of 3,997 newly diagnosed Alzheimer's patients from 17 hospitals compared treatment patterns before (Cohort 1) and after (Cohort 2) the LTCI revision, revealing that Cohort 2 had a longer duration of initial treatment and lower treatment discontinuation rates.
- - Despite similar cognitive scores at diagnosis, patients from Cohort 2 showed improved treatment outcomes, indicating that the revised LTCI system positively influenced care for Alzheimer's patients in South Korea. *
Patterns of use of symptomatic treatments for Alzheimer's disease dementia (AD).
BMC Neurol
November 2023
Epidemiology, Biostatistics and Research Decision Sciences, Merck & Co., Inc., 770 Sumneytown Pike, West Point, PA, 19486, USA.
Background: Symptomatic treatment for Alzheimer's disease (AD) dementia could temporarily slow symptom worsening and improve the quality of life for both AD dementia patients and their caregivers. A comprehensive evaluation of symptomatic treatment patterns using recent data for newly diagnosed AD dementia has not been performed and compared across different countries.
Methods: The drug name, time to the first therapy, duration, discontinuation or switches were described in newly diagnosed AD dementia patients in two databases (a major U.
Action Myoclonus Secondary to Donepezil: Case Report and Literature Review.
Rambam Maimonides Med J
October 2023
Medicine Department, Federal University of Santa Maria, Santa Maria, Brazil.
Movement disorders associated with donepezil have been only rarely reported. Herein, we describe an older woman who developed myoclonus secondary to donepezil. A 61-year-old female presented with brief involuntary twitching.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!